live, attenuated herpes zoster vaccine

Trade name: varilrix

Vaccineexperimental

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine are more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of the disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin. Another vaccine, known as zoster vaccine, is used to prevent diseases caused by the same virus – the varicella zoster virus. — Wikipedia

Clinical trial activity

26 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
23
Phase 3
21
Phase 4
2

Earliest trial started Feb 1, 2007 (NCT00434577)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gsk 1437173
  • gsk1437173a
  • gsk 1437173a
  • gsk208133
  • live attenuated chicken pox vaccine
  • varilrix

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03314103Phase 3Oct 6, 2017Government of China
NCT02979639Phase 3Jan 16, 2017GlaxoSmithKline
NCT02723773Phase 3Apr 16, 2016GlaxoSmithKline
NCT02735915Phase 3Apr 11, 2016GlaxoSmithKline
NCT02690207Phase 3Mar 16, 2016GlaxoSmithKline
NCT02581410Phase 3Dec 1, 2015GlaxoSmithKline
NCT02570126Phase 3Nov 1, 2015GlaxoSmithKline
NCT02383797Phase 4Feb 1, 2015University of Helsinki
NCT02075515Phase 3Aug 13, 2014GlaxoSmithKline
NCT02058589Phase 3Mar 20, 2014GlaxoSmithKline
NCT02045836Phase 3Mar 1, 2014GlaxoSmithKline
NCT02052596Phase 3Feb 7, 2014GlaxoSmithKline
NCT01954251Phase 3Oct 1, 2013GlaxoSmithKline
NCT01777321Phase 3Jun 17, 2013GlaxoSmithKline
NCT01827839Phase 3Jun 10, 2013GlaxoSmithKline
NCT01798056Phase 3Mar 1, 2013GlaxoSmithKline
NCT01767467Phase 3Mar 1, 2013GlaxoSmithKline
NCT01751165Phase 3Mar 1, 2013GlaxoSmithKline
NCT01610414Phase 3Jul 13, 2012GlaxoSmithKline
NCT01439360Phase 3Oct 1, 2011GlaxoSmithKline
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit232332007
Cairo UniversityAcademic/Hospital1112010
Government of ChinaGovernment1112017
University of HelsinkiAcademic/Hospital1112015
4 organizations
Page 1 / 1